Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fibrogen Inc CS (NQ: FGEN )

17.78 +0.65 (+3.79%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,447,775
Open 16.95
Bid (Size) 17.16 (6)
Ask (Size) 18.00 (2)
Prev. Close 17.13
Today's Range 16.47 - 17.92
52wk Range 8.670 - 25.69
Shares Outstanding 97,582,416
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Couchbase Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Mobiquity Technologies, Inc. (NASDAQ: MOBQ) shares gained 124% to $0.3325. Mobiquity Technologies launched ElecAlytics, an AI-Powered analytics suite added to its ElecTech platform for... 
Via Benzinga
FibroGen Stock Plunges Under Key Lines As Lead Drug Fails; Why Hope Isn't Lost
The company's lead drug didn't improve upper-limb mobility for some patients with the disease. 
Via Investor's Business Daily

Performance

YTD
+11.47%
+11.47%
1 Month
+0.06%
+0.06%
3 Month
-15.45%
-15.45%
6 Month
+15.23%
+15.23%
1 Year
+69.33%
+69.33%

More News

Read More
FibroGen's One Study For Duchenne Muscular Dystrophy Fails To Hit Main Goal
Via Benzinga
FibroGen's Return on Invested Capital Overview
Via Benzinga
FibroGen's Anemia Candidate Fails In Myelodysplastic Syndrome Study
Via Benzinga
FibroGen Earnings Preview
Via Benzinga
FibroGen's Return On Capital Employed Insights
Via Benzinga
FibroGen Stock Joins Rank Of Stocks With RS Ratings Over 90
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2023
Via Benzinga
Why did Sarepta Therapeutics Stock Plummet?
Via MarketBeat
Exposures Product Safety
Analyst Ratings for FibroGen
Via Benzinga
Earnings Preview For FibroGen
Via Benzinga
B of A Securities Upgrades FibroGen: Here's What You Need To Know
Via Benzinga
Short Volatility Alert: FibroGen, Inc.
Via Benzinga
Earnings Scheduled For February 27, 2023
Via Benzinga
FibroGen Shares Gain As Analyst Creates Bullish Pitch On Pulmonary Fibrosis Opportunity
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2023
Via Benzinga
Why ABVC BioPharma Shares Are Trading Higher By 129%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Perrigo, Tripadvisor, Lyft, And Some Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Via Benzinga
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
FibroGen Earnings Preview
Via Benzinga
7 Unknown Biotech Stocks That Could Rocket in 2023
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.